New hope for stubborn liver disease: trial tests Second-Line drug
NCT ID NCT06247735
Summary
This study is testing whether a drug called pemafibrate (K-808) can help control primary biliary cholangitis (PBC), a chronic liver disease, in people whose liver tests remain high despite taking standard medications. About 46 adults who haven't responded well to their current PBC treatments will receive either the new drug or a placebo for 12 weeks, with an option to continue for a year. The main goal is to see if the drug safely lowers a key liver enzyme (ALP) compared to a dummy pill.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
(G.I,R,I) GI Research Institute
Vancouver, British Columbia, V6Z 2K5, Canada
-
302
Sapporo, Japan
-
303
Itabashi-ku, Japan
-
304
Isehara, Japan
-
305
Hamamatsu, Japan
-
306
Fukui, Japan
-
307
Matsumoto, Japan
-
308
Hirakata, Japan
-
309
Hiroshima, Japan
-
311
Ōmura, Japan
-
312
Kanazawa, Japan
-
313
Fukuoka, Japan
-
314
Yokohama, Japan
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)
Montreal, Quebec, H2X 0A9, Canada
-
CommonSpirit Health Research Institute
Omaha, Nebraska, 68124, United States
-
Einstein Medical Center
Philadelphia, Pennsylvania, 19141, United States
-
Florida Research Institute
Lakewood Rch, Florida, 34211, United States
-
Gastrointestinal and Liver Specialists of Tidewater - Digestive and Liver Disease Specialists
Norfolk, Virginia, 23502, United States
-
Liver Institute Northwest
Seattle, Washington, 98105, United States
-
Mercy Medical Center - Mcauley Plaza
Baltimore, Maryland, 21202, United States
-
New York University Hepatology Associates
New York, New York, 10016, United States
-
Office of Dr. Gauthier
North Bay, Ontario, P1B 2H3, Canada
-
Peak Gastroenterology Associates Colorado Springs
Colorado Springs, Colorado, 80921, United States
-
Pioneer Research Solutions
Houston, Texas, 77099, United States
-
Rapid City Medical Center
Rapid City, South Dakota, 57701, United States
-
Southern California Research Center - Coronado
Coronado, California, 92118, United States
-
Springfield Clinic
Springfield, Illinois, 62702, United States
-
Teine Keijinkai Hospital
Sapporo, Japan
-
Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
-
UA Thomas D. Boyer Liver Institute
Tucson, Arizona, 85724, United States
-
UVA Health - University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of Florida Hepatology Research at CTRB
Gainesville, Florida, 32610, United States
-
University of Miami Leonard M. Miller School of Medicine
Miami, Florida, 33136, United States
-
Vanderbilt Digestive Disease Center
Nashville, Tennessee, 37232, United States
-
Velocity Clinical Research
Santa Ana, California, 92704, United States
-
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.